Alzheimer’s Disease: A New Era of Disease-Modifying Therapies Emerges
The Alzheimer’s disease (AD) treatment landscape is entering a new era, driven by the emergence of disease-modifying therapies. The full approvals of anti-amyloid antibodies Leqembi (lecanemab) and Kisunla (donanemab) mark a pivotal shift from symptomatic management to targeting the underlying pathology of AD. These biologics are expected to create a multibillion-dollar market, particularly in early-stage disease, where unmet need remains high.
Despite lingering questions around efficacy and safety—especially concerning amyloid-related imaging abnormalities (ARIA)—the market outlook is optimistic. Leqembi’s favorable safety profile and rapid uptake position it as a front-runner, while donanemab’s potential for limited treatment duration may appeal to payers. Meanwhile, the agitation segment is evolving with the approval of Rexulti and the anticipated launches of Auvelity and Igalmi.
This report provides a comprehensive analysis of the AD market across the US, Japan, and five major European markets, with a 10-year patient-based forecast and deep dives into pipeline innovation, biomarker-driven segmentation, and evolving treatment paradigms.
In this report we cover:
- Key growth drivers: Full approvals of Leqembi and Kisunla, increasing biomarker-based diagnosis, and rising prevalence in aging populations.
- Promising therapies: Leqembi, Kisunla, Rexulti, and upcoming entrants like Auvelity and Igalmi.
- Market evolution: Transition from symptomatic treatments to disease-modifying therapies and targeted neuropsychiatric interventions.
